Overview

Amivantamab, Lazertinib, Carboplatin and Pemetrexed for First-line Treatment of Recurrent / Metastatic Non-small Cell Lung Cancers With Epidermal Growth Factor Receptor Mutations (AMIGO-1)

Status:
Not yet recruiting

Trial end date:
2025-12-01

Target enrollment:

Participant gender:

Summary

This is a phase II, single-arm, multicenter trial. Treatment-naïve patients with recurrent/metastatic NSCLCs harboring EGFR exon 19 deletions or exon 21 Leucine858Arginine (L858R) point mutations will be enrolled.

Phase:

Phase 2

Details

Lead Sponsor:

Latin American Cooperative Oncology Group

Collaborator:

Janssen, LP

Treatments:

Carboplatin
Lazertinib
Pemetrexed